Abpro Holdings, Inc. (ABPWW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
6 ST JOHNS LANE, FLOOR 5 NEW YORK, NY 10013 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 2,850 | 265 | 392 | |||
| Cash and cash equivalent | 2,850 | 265 | 392 | |||
| Restricted cash and investments | 142 | |||||
| Receivables | 323 | |||||
| Prepaid expense | 378 | |||||
| Asset, held-in-trust | 29,729 | |||||
| Other undisclosed current assets | 461 | |||||
| Total current assets: | 3,776 | 29,994 | 770 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 418 | |||||
| Property, plant and equipment | 37 | |||||
| Asset, held-in-trust | 7,372 | 309,790 | ||||
| Restricted cash and investments | 142 | |||||
| Other undisclosed noncurrent assets | 288 | |||||
| Total noncurrent assets: | 885 | 7,372 | 309,790 | |||
| TOTAL ASSETS: | 4,661 | 37,366 | 310,561 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 11,432 | 469 | 1,243 | |||
| Accounts payable | 3,936 | |||||
| Accrued liabilities | 7,496 | 469 | 1,243 | |||
| Debt | 2,725 | |||||
| Financial instruments subject to mandatory redemption, settlement terms, share value, amount | 29,729 | |||||
| Other undisclosed current liabilities | 5,450 | 5,190 | 899 | |||
| Total current liabilities: | 19,607 | 35,388 | 2,142 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 10,500 | 10,500 | ||||
| Deferred compensation liability, classified | 10,500 | 10,500 | ||||
| Other undisclosed noncurrent liabilities | 0 | |||||
| Total noncurrent liabilities: | 10,500 | 10,500 | ||||
| Total liabilities: | 19,607 | 45,888 | 12,642 | |||
| Temporary equity, including noncontrolling interest | 7,293 | 309,098 | ||||
| Equity | ||||||
| Equity, attributable to parent, including: | (15,495) | (15,815) | (11,179) | |||
| Common stock | 5 | |||||
| Additional paid in capital | 100,603 | |||||
| Accumulated deficit | (116,103) | (15,816) | (11,180) | |||
| Other undisclosed equity, attributable to parent | 1 | 1 | ||||
| Equity, attributable to noncontrolling interest | 549 | |||||
| Other undisclosed equity | (0) | |||||
| Total equity: | (14,946) | (15,815) | (11,179) | |||
| TOTAL LIABILITIES AND EQUITY: | 4,661 | 37,366 | 310,561 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Revenues | 183 | ||||
| Other income | 3,556 | ||||
| Cost of revenue (Cost of Product and Service Sold) | (1,268) | ||||
| Other undisclosed gross profit | |||||
| Gross profit: | (1,085) | ||||
| Operating expenses | (10,104) | ||||
| Other undisclosed operating income (loss) | 1,268 | (1,666) | (2,050) | ||
| Operating loss: | (9,921) | (1,666) | (2,050) | ||
| Nonoperating income | 2,689 | 5,665 | 3,761 | ||
| Other nonoperating income | 3,556 | ||||
| Interest and debt expense | 173 | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (7,059) | 3,999 | 1,711 | ||
| Other undisclosed loss from continuing operations before income taxes | (173) | ||||
| Income (loss) from continuing operations before income taxes: | (7,232) | 3,999 | 1,711 | ||
| Income tax expense | (1,177) | (824) | |||
| Other undisclosed income from continuing operations | |||||
| Income (loss) from continuing operations: | (7,232) | 2,821 | 887 | ||
| Other undisclosed net income | |||||
| Net income (loss) attributable to parent: | (7,232) | 2,821 | 887 | ||
| Preferred stock dividends and other adjustments | 29,729 | ||||
| Net income (loss) available to common stockholders, diluted: | (7,232) | 32,550 | 887 | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Net income (loss): | (7,232) | 2,821 | 887 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (7,232) | 2,821 | 887 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.